NeuroDerm Funding: How Much Did They Raise & Key Investors

How Much Did NeuroDerm Raise?
Funding & Key Investors

NeuroDerm has successfully secured a significant capital infusion, bringing its total funding to $132.9M. This latest major strategic investment of $66.9M underscores the market confidence in the company's specialized approach to central nervous system disorders. By bridging the gap between pharmaceutical efficacy and medical technology, NeuroDerm continues to solidify its position as a leader in the development of patient-centric therapeutic solutions for complex neurological conditions.

The company's trajectory, marked by a series of strategic financing rounds, reflects a robust commitment to advancing its flagship drug-device combination therapy. This recent influx of capital serves as a critical catalyst for scaling operations and accelerating the clinical development pipeline, ensuring that innovative treatments reach the patient population with greater efficiency and precision.

What is NeuroDerm?

NeuroDerm

Manufacturing

Pharmaceuticals

Business Services

NeuroDerm operates at the intersection of pharmaceutical research and medical device engineering, specifically targeting the unmet needs of patients suffering from Parkinson's disease. The company's core value proposition lies in its ability to integrate advanced drug delivery systems with digital health solutions, effectively mitigating the motor fluctuations that characterize the disease. By focusing on the patient experience, NeuroDerm is not merely developing a drug, but a comprehensive ecosystem designed to improve long-term health outcomes and quality of life for those managing chronic neurological burdens. Their market position is defined by a high-barrier-to-entry model that combines proprietary hardware with specialized pharmacological formulations.

How much funding has NeuroDerm raised?

NeuroDerm has raised a total of $132.9M across 4 funding rounds:

2013

Unspecified

$5M

2014

Unspecified

$16M

Stock Offering

$45M

2015

Stock Offering

$66.9M

Unspecified (2013): $5M, investors not publicly disclosed

Unspecified (2014): $16M led by Elias Group

Stock Issuance/Offering (2014): $45M, investors not publicly disclosed

Stock Issuance/Offering (2015): $66.9M, investors not publicly disclosed

Key Investors in NeuroDerm

Elias Group

A specialized investment firm focused on identifying high-growth opportunities within the life sciences and healthcare technology sectors.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for NeuroDerm?

With the recent capital injection, NeuroDerm is well-positioned to transition into a more mature phase of commercialization and clinical expansion. The strategic roadmap likely involves the finalization of regulatory milestones for its lead candidate, ND0612, and the potential expansion of its digital health infrastructure to enhance healthcare connectivity. As the company scales, the focus will shift toward market penetration and the establishment of long-term partnerships within the global MedTech landscape. Investors are closely monitoring the company's ability to translate its R&D success into sustainable, enterprise-level growth, particularly as it seeks to redefine the standard of care for Parkinson's disease patients worldwide.

See full NeuroDerm company page

See More Financial Insights